Table of Contents

company-logo

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

Fusion Antibodies Dividend Announcement

• Fusion Antibodies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Fusion Antibodies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Fusion Antibodies Dividend History

Fusion Antibodies Dividend Yield

Fusion Antibodies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Fusion Antibodies stock? Use our calculator to estimate your expected dividend yield:

Fusion Antibodies Financial Ratios

P/E ratio-0.97
PEG ratio2.92
P/B ratio1.21
ROE-137.11%
Payout ratio0.00%
Current ratio3.87
Quick ratio3.09
Cash Ratio2.05

Fusion Antibodies Dividend FAQ

Does Fusion Antibodies stock pay dividends?
Fusion Antibodies does not currently pay dividends to its shareholders.
Has Fusion Antibodies ever paid a dividend?
No, Fusion Antibodies has no a history of paying dividends to its shareholders. Fusion Antibodies is not known for its dividend payments.
Why doesn't Fusion Antibodies pay dividends?
There are several potential reasons why Fusion Antibodies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Fusion Antibodies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Fusion Antibodies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Fusion Antibodies a dividend aristocrat?
Fusion Antibodies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Fusion Antibodies a dividend king?
Fusion Antibodies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Fusion Antibodies a dividend stock?
No, Fusion Antibodies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Fusion Antibodies stocks?
To buy Fusion Antibodies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Fusion Antibodies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.